Research programme: natural killer cell cancer therapies - NantKwest

Drug Profile

Research programme: natural killer cell cancer therapies - NantKwest

Alternative Names: CD19 target activated natural killer cellular therapy - NantKwest; CD19.t-haNK; CD19.t-haNK therapy - NantKwest; CD19.taNK therapy - NantKwest; CS1 target activated natural killer cellular therapy- NantKwest; CS1.taNK therapy - NantKwest; CST 102; CST 103; NANT Cancer Vaccine; NK 92 [CD16.158V, ER IL-2]; t-haNK -NantKwest; ZRx 102; ZRx 103; ZRx 104

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZelleRx
  • Developer NantKwest
  • Class CAR-NK cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Cell death stimulants; Immunostimulants; Natural killer cell stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours; Squamous cell cancer

Most Recent Events

  • 12 Mar 2018 NantKwest plans a clinical trial of CD19.t-haNK for Cancer
  • 12 Mar 2018 NantKwest plans a pahse Ib/II trial of CD19.t-haNK for Cancer (In combination with NANT Cancer Vaccine)
  • 04 Apr 2017 NantKwest and Viracta Therapeutics enter into a collaboration agreement to investigate combination of natural killer cells and VRx 3996 in broad range of cancers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top